AbbVie Inc. is recalling approximately 568 units of AndroGel (testosterone gel) 1.62% in both metered-dose pumps and individual foil packets. This recall was initiated because the medication was exposed to temperatures outside of the recommended storage conditions for an extended period, which could affect how well the drug works. These products were distributed specifically in Arizona and include both the 88-gram pump and the 2.5-gram aluminum foil packets.
Prolonged exposure to temperatures outside the labeled range—known as temperature abuse—can degrade the active ingredient, potentially resulting in a loss of potency. This means the medication may not provide the intended dose of testosterone required for treatment.
Healthcare provider consultation and pharmacy refund
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.